Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
55.6M
-
Number of holders
-
32
-
Total 13F shares, excl. options
-
16.1M
-
Shares change
-
+146K
-
Total reported value, excl. options
-
$51M
-
Value change
-
+$462K
-
Number of buys
-
10
-
Number of sells
-
-3
-
Price
-
$3.17
Significant Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q1 2023
32 filings reported holding XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2023.
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) has 32 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.1M shares
of 55.6M outstanding shares and own 28.93% of the company stock.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (2.81M shares), Atlas Venture Life Science Advisors, LLC (2.76M shares), Octagon Capital Advisors LP (2.43M shares), FMR LLC (1.91M shares), RiverVest Venture Management LLC (1.44M shares), Rock Springs Capital Management LP (1.44M shares), VANGUARD GROUP INC (890K shares), Artal Group S.A. (450K shares), HARVARD MANAGEMENT CO INC (416K shares), and Trustees of Columbia University in the City of New York (250K shares).
This table shows the top 32 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.